Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients

Transfusion

Volumn 51, Issue 12, 2011, Pages 2611-2618

  Fontaine, Magali J ^a,b   Kuo, Jenny ^a,b   Chen, Ge ^a,b   Galel, Susan A ^a,b   Miller, Evelyn ^a,b   Sequeira, Flavia ^a,b   Viele, Maurene ^a,b   Goodnough, Lawrence T ^a,b   Tyan, Dolly B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCULATED PERCENT REACTIVE ANTIBODY; COMPLEMENT COMPONENT C1Q; HLA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; APLASTIC ANEMIA; ARTICLE; BLOOD GROUP ABO SYSTEM; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRECTED COUNT INCREMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOASSAY; MALE; SINGLE ANTIGEN BEAD ASSAY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPHERESIS;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BIOLOGICAL ASSAY; BLOOD PLATELETS; COMPLEMENT C1Q; DONOR SELECTION; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; MALE; MIDDLE AGED;

EID: 83555165281     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03194.x     Document Type: Article

References (21)

1. Friedberg RC, Mintz PD,. Causes of refractoriness to platelet transfusion. Curr Opin Hematol 1995; 2: 493-8.
2. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH,. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994; 66: 200-5. (Pubitemid 24103656)
3. Fabris F, Soini B, Sartori R, Randi ML, Luzzatto G, Girolami A,. Clinical and laboratory factors that affect the post-transfusion platelet increment. Transfus Sci 2000; 23: 63-8. (Pubitemid 30484108)
4. Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, D'Agati VD, Cohen DJ, Ratner LE, Suciu-Foca N,. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589-94.
5. Patel R, Terasaki PI,. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-9.
6. Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhmig GA,. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275: 149-60. (Pubitemid 36351550)
7. Smith JD, Hamour IM, Banner NR, Rose ML,. C4d fixing, Luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809-15. (Pubitemid 350045767)
8. Chen G, Sequeira F, Tyan D,. C1q-IVIG assay predicts IVIG efficacy in vivo [abstract]. Human Immunol 2009; 70 (S1): 45.
9. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, Rosenthal D, Reinhartz O, Tyan D,. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158-63.
10. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB,. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342-7.
11. Aubuchon JP,. Hemotherapy decisions and their outcomes. In:, Roback JD, Rae Combs M, Grossman B, Hillyer CD, editor. Technical manual. 16th ed. Bethesda (MD): American Association of Blood Banks; 2008. p. 579-89.
12. United Network for Organ Sharing. UNOS centralized computer network, UNet. 2011. [cited 2011 May 9]. Available from: URL
13. Hod E, Schwartz J,. Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348-60. (Pubitemid 351962170)
14. Schiffer CA,. Diagnosis and management of refractoriness to platelet transfusion. Blood Rev 2001; 15: 175-80. (Pubitemid 34464475)
15. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM,. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-56. (Pubitemid 32048531)
16. Tait BD, Hudson F, Cantwell L, Brewin G, Holdsworth R, Bennett G, Jose M,. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology 2009; 14: 247-54.
17. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW,. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75: 408-13. (Pubitemid 20233287)
18. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N,. The role of ABO matching in platelet transfusion. Eur J Haematol 1993; 50: 110-7. (Pubitemid 23061276)
19. Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K,. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009; 49: 21-33.
20. Lee EJ, Schiffer CA,. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989; 29: 384-9. (Pubitemid 19196221)
21. Lozano M, Heddle N, Williamson LM, Wang G, AuBuchon JP, Dumont LJ,; Biomedical Excellence for Safer Transfusion Collaborative. Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey. Transfusion 2010; 50: 1743-8.